Physician profile
Deborah E Lampley
NPI 1598941866
$2,151.45
in general payments reported to CMS, 2019-2025
16 companies · $15.51 in 2025
The $15.51 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,179 · 2022: $397 · 2023: $544 · 2024: $15.95 · 2025: $15.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $859.39 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $346.45 | 2021-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $191.92 | 2021-2023 | Mounjaro |
| Sunovion Pharmaceuticals INC. | $144.17 | 2021 | |
| Pfizer INC. | $90.84 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.68 | 2021-2023 | Synjardy, Jardiance |
| Abbott Laboratories | $70.34 | 2022-2023 | Freestyle Libre 3 |
| Abbvie INC. | $63.03 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $59.04 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $50.16 | 2021-2023 | Belsomra, Lagevrio |
| Bayer Healthcare Pharmaceuticals INC. | $49.34 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $46.75 | 2023 | Rexulti |
| Exact Sciences Corporation | $35.87 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $21.27 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $16.99 | 2023 | Farxiga |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $15.21 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Lampley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.